East Ventures Leads Investment in Microbiome Startup from Singapore AMILI
AMILI will expand operations to Indonesia with a main focus on treating intestinal health problems
East Ventures is leading investment to AMILI, a startup from Singapore that claims to be the first and only gut microbiome precision medicine in Southeast Asia. No mention of the nominal funding provided.
In its official statement, this investment is said to strengthen AMILI's capital after securing series A funding in June 2022. The plan is for AMILI to expand its business operations to Indonesia with the main focus on dealing with intestinal health problems adapted to Indonesian market conditions.
AMILI was founded in 2019 by Dr. Jeremy Lim (CEO), Drs. David Ong, and Jonathan Lee. The three of them were noted to have led the gut microbiome transplant at the National University Hospital in 2014 as well as the first in the Southeast Asian region.
Purchase to keep reading and accessing this article